Mismanagement and potential fraud have emerged in recent months in Delaware’s quarter-billion-dollar program to combat the opioid epidemic, even as the state’s strategy for doling out the money was supposed to be better, and more efficient, than what was done elsewhere.
In 2021, Delaware lawmakers created a new commission to recommend where money from the state’s many legal settlements with opioid manufacturers and distributors should go. That commission, run by Lt. Gov. Bethany Hall-Long’s office, has been at the heart of the issues surrounding Delaware’s opioid fund.
